Search hospitals > Ohio > Dayton
Midwest Clinical Research Center
Claim this profileDayton, Ohio 45417
Global Leader in Depression
Global Leader in Major Depressive Disorder
Conducts research for Schizophrenia
Conducts research for Anxiety Disorders
Conducts research for Allergic Rhinitis
182 reported clinical trials
3 medical researchers
Summary
Midwest Clinical Research Center is a medical facility located in Dayton, Ohio. This center is recognized for care of Depression, Major Depressive Disorder, Schizophrenia, Anxiety Disorders, Allergic Rhinitis and other specialties. Midwest Clinical Research Center is involved with conducting 182 clinical trials across 92 conditions. There are 3 research doctors associated with this hospital, such as Richard D Sanders, MD, Otto Dueno, MD, and Syed Najeed, MD.Top PIs
Richard D Sanders, MDMidwest Clinical Research Center1 year of reported clinical research
Studies Schizophrenia
2 reported clinical trials
3 drugs studied
Otto Dueno, MDMidwest Clinical Research Center2 years of reported clinical research
Studies Methamphetamine Abuse
Studies Methamphetamine Addiction
1 reported clinical trial
2 drugs studied
Syed Najeed, MDMidwest Clinical Research Center1 year of reported clinical research
Studies Bunions
1 reported clinical trial
1 drug studied
Clinical Trials running at Midwest Clinical Research Center
Depression
Schizophrenia
Major Depressive Disorder
Chronic Urticaria
Multiple Sclerosis
Hives
Bunions
Bipolar Disorder
Postoperative Pain
Sjogren's Syndrome
Aticaprant
for Depression
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Recruiting2 awards Phase 316 criteria
Aticaprant
for Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Recruiting1 award Phase 36 criteria
BI 1569912
for Depression
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2 to 4 and a half months. During this time, they visit the study site at least 6 times. At the visits, doctors ask participants about their symptoms. The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants.
Recruiting0 awards Phase 23 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Midwest Clinical Research Center?
Midwest Clinical Research Center is a medical facility located in Dayton, Ohio. This center is recognized for care of Depression, Major Depressive Disorder, Schizophrenia, Anxiety Disorders, Allergic Rhinitis and other specialties. Midwest Clinical Research Center is involved with conducting 182 clinical trials across 92 conditions. There are 3 research doctors associated with this hospital, such as Richard D Sanders, MD, Otto Dueno, MD, and Syed Najeed, MD.